| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stress Disorders, Post-Traumatic | 44 | 2021 | 4575 | 3.610 |
Why?
|
| Pregnanolone | 12 | 2021 | 67 | 2.720 |
Why?
|
| Neuropeptide Y | 8 | 2017 | 192 | 1.340 |
Why?
|
| Progesterone | 7 | 2021 | 742 | 1.100 |
Why?
|
| Tobacco Use Disorder | 4 | 2023 | 703 | 1.090 |
Why?
|
| Neurotransmitter Agents | 4 | 2018 | 665 | 1.030 |
Why?
|
| Menstrual Cycle | 8 | 2021 | 539 | 0.950 |
Why?
|
| Dehydroepiandrosterone | 7 | 2018 | 258 | 0.950 |
Why?
|
| Follicular Phase | 5 | 2021 | 143 | 0.950 |
Why?
|
| Luteal Phase | 5 | 2021 | 138 | 0.950 |
Why?
|
| Steroids | 2 | 2018 | 929 | 0.810 |
Why?
|
| Exercise Therapy | 2 | 2020 | 929 | 0.750 |
Why?
|
| Dissociative Disorders | 6 | 2016 | 234 | 0.710 |
Why?
|
| Smoking Cessation | 3 | 2023 | 2057 | 0.690 |
Why?
|
| Stress, Psychological | 13 | 2017 | 4481 | 0.640 |
Why?
|
| Hydrocortisone | 13 | 2012 | 1819 | 0.610 |
Why?
|
| Dehydroepiandrosterone Sulfate | 5 | 2018 | 241 | 0.580 |
Why?
|
| Pituitary-Adrenal System | 5 | 2021 | 552 | 0.580 |
Why?
|
| Hypothalamo-Hypophyseal System | 5 | 2021 | 701 | 0.540 |
Why?
|
| Endophenotypes | 1 | 2018 | 255 | 0.530 |
Why?
|
| Sweat Glands | 1 | 2016 | 33 | 0.530 |
Why?
|
| Stress, Physiological | 8 | 2016 | 1403 | 0.530 |
Why?
|
| Premenstrual Syndrome | 1 | 2016 | 109 | 0.520 |
Why?
|
| Habituation, Psychophysiologic | 1 | 2016 | 147 | 0.510 |
Why?
|
| Rape | 1 | 2016 | 131 | 0.500 |
Why?
|
| Neuroanatomy | 1 | 2015 | 70 | 0.480 |
Why?
|
| Body Temperature Regulation | 1 | 2016 | 292 | 0.470 |
Why?
|
| Hormones | 1 | 2018 | 869 | 0.460 |
Why?
|
| Panic Disorder | 2 | 2016 | 613 | 0.460 |
Why?
|
| Galvanic Skin Response | 1 | 2016 | 358 | 0.460 |
Why?
|
| Neurobiology | 1 | 2015 | 137 | 0.450 |
Why?
|
| Sympathetic Nervous System | 1 | 2016 | 518 | 0.430 |
Why?
|
| Neuropeptides | 1 | 2018 | 944 | 0.410 |
Why?
|
| Adult Survivors of Child Abuse | 1 | 2016 | 294 | 0.410 |
Why?
|
| Phobic Disorders | 1 | 2015 | 439 | 0.400 |
Why?
|
| 5-alpha-Dihydroprogesterone | 3 | 2018 | 5 | 0.390 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2017 | 455 | 0.370 |
Why?
|
| Combat Disorders | 3 | 2017 | 301 | 0.360 |
Why?
|
| Fluoxetine | 3 | 2012 | 733 | 0.350 |
Why?
|
| Yohimbine | 3 | 2003 | 62 | 0.350 |
Why?
|
| Adrenergic alpha-Antagonists | 2 | 2000 | 174 | 0.320 |
Why?
|
| Receptors, GABA-A | 3 | 2018 | 623 | 0.320 |
Why?
|
| Hydroxysteroid Dehydrogenases | 2 | 2018 | 29 | 0.320 |
Why?
|
| Fear | 9 | 2021 | 1477 | 0.310 |
Why?
|
| Disability Evaluation | 1 | 2016 | 1836 | 0.310 |
Why?
|
| Veterans | 9 | 2019 | 2649 | 0.260 |
Why?
|
| Pain | 1 | 2020 | 5073 | 0.250 |
Why?
|
| Sex Characteristics | 1 | 2015 | 2639 | 0.250 |
Why?
|
| Depressive Disorder | 3 | 2016 | 3728 | 0.240 |
Why?
|
| Comorbidity | 9 | 2018 | 10508 | 0.240 |
Why?
|
| Anxiety | 4 | 2021 | 4573 | 0.230 |
Why?
|
| Smoking | 3 | 2023 | 9053 | 0.230 |
Why?
|
| Health Status | 1 | 2016 | 4077 | 0.210 |
Why?
|
| Adult | 42 | 2021 | 221210 | 0.210 |
Why?
|
| Adrenal Glands | 1 | 2004 | 552 | 0.190 |
Why?
|
| Extinction, Psychological | 2 | 2016 | 371 | 0.190 |
Why?
|
| Dentate Gyrus | 1 | 2002 | 164 | 0.190 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2006 | 625 | 0.190 |
Why?
|
| Affect | 3 | 2013 | 1486 | 0.180 |
Why?
|
| Female | 39 | 2021 | 392705 | 0.180 |
Why?
|
| Humans | 61 | 2023 | 761596 | 0.180 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2015 | 928 | 0.170 |
Why?
|
| Cholestenone 5 alpha-Reductase | 1 | 2018 | 21 | 0.160 |
Why?
|
| Psychiatric Status Rating Scales | 9 | 2017 | 6019 | 0.160 |
Why?
|
| Exercise | 1 | 2016 | 5890 | 0.160 |
Why?
|
| Tourette Syndrome | 3 | 1997 | 395 | 0.160 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 2 | 2021 | 895 | 0.150 |
Why?
|
| GABA Agents | 1 | 2018 | 41 | 0.150 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2002 | 602 | 0.150 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 1998 | 69 | 0.150 |
Why?
|
| Androstane-3,17-diol | 1 | 2017 | 20 | 0.150 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2018 | 353 | 0.150 |
Why?
|
| Male | 37 | 2021 | 360846 | 0.150 |
Why?
|
| Glucocorticoids | 3 | 2017 | 2161 | 0.150 |
Why?
|
| Mood Disorders | 1 | 2004 | 1127 | 0.150 |
Why?
|
| Premenopause | 1 | 2001 | 1039 | 0.140 |
Why?
|
| Cues | 1 | 2002 | 875 | 0.140 |
Why?
|
| Midwestern United States | 1 | 2016 | 70 | 0.130 |
Why?
|
| Military Personnel | 6 | 2019 | 1246 | 0.130 |
Why?
|
| Receptors, GABA | 1 | 2018 | 313 | 0.130 |
Why?
|
| Pilot Projects | 3 | 2018 | 8633 | 0.130 |
Why?
|
| 8-Hydroxy-2-(di-n-propylamino)tetralin | 1 | 1994 | 32 | 0.120 |
Why?
|
| Ghrelin | 1 | 2017 | 252 | 0.120 |
Why?
|
| Down-Regulation | 1 | 2002 | 2919 | 0.120 |
Why?
|
| Substance Abuse Detection | 1 | 2018 | 301 | 0.120 |
Why?
|
| Infrared Rays | 1 | 2016 | 247 | 0.120 |
Why?
|
| Tryptophan | 1 | 1997 | 482 | 0.120 |
Why?
|
| Young Adult | 10 | 2021 | 59260 | 0.120 |
Why?
|
| Affective Symptoms | 1 | 2017 | 417 | 0.120 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2021 | 1141 | 0.120 |
Why?
|
| Brain Injuries | 2 | 2019 | 2054 | 0.120 |
Why?
|
| Afghan Campaign 2001- | 1 | 2015 | 298 | 0.120 |
Why?
|
| Thinness | 1 | 2017 | 490 | 0.110 |
Why?
|
| Serotonin Receptor Agonists | 1 | 1994 | 151 | 0.110 |
Why?
|
| Gastric Mucosa | 1 | 2017 | 604 | 0.110 |
Why?
|
| Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2014 | 88 | 0.110 |
Why?
|
| Middle Aged | 17 | 2021 | 220921 | 0.100 |
Why?
|
| Constipation | 1 | 2017 | 563 | 0.100 |
Why?
|
| Carbon Dioxide | 1 | 2016 | 1147 | 0.100 |
Why?
|
| Depression | 5 | 2017 | 8126 | 0.100 |
Why?
|
| Cross-Over Studies | 2 | 2017 | 2079 | 0.100 |
Why?
|
| Pain Threshold | 1 | 2016 | 604 | 0.100 |
Why?
|
| Menopause | 1 | 2019 | 1646 | 0.100 |
Why?
|
| Potassium Channels | 1 | 2014 | 537 | 0.090 |
Why?
|
| Saliva | 5 | 2012 | 828 | 0.090 |
Why?
|
| Case-Control Studies | 4 | 2016 | 22176 | 0.090 |
Why?
|
| Prefrontal Cortex | 4 | 1999 | 2220 | 0.090 |
Why?
|
| Obsessive-Compulsive Disorder | 2 | 1997 | 1491 | 0.090 |
Why?
|
| Valproic Acid | 1 | 2013 | 443 | 0.090 |
Why?
|
| Conditioning, Classical | 1 | 2013 | 368 | 0.090 |
Why?
|
| Severity of Illness Index | 7 | 2018 | 15843 | 0.090 |
Why?
|
| Police | 1 | 2012 | 157 | 0.090 |
Why?
|
| Diarrhea | 1 | 2017 | 1318 | 0.090 |
Why?
|
| Estradiol | 1 | 2017 | 1937 | 0.080 |
Why?
|
| Double-Blind Method | 5 | 2017 | 12341 | 0.080 |
Why?
|
| Behavior, Animal | 3 | 2012 | 1878 | 0.080 |
Why?
|
| Up-Regulation | 2 | 2012 | 4125 | 0.080 |
Why?
|
| Animals | 14 | 2017 | 168475 | 0.080 |
Why?
|
| Anorexia Nervosa | 1 | 2017 | 1361 | 0.080 |
Why?
|
| Brain | 4 | 2019 | 27121 | 0.080 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2013 | 774 | 0.080 |
Why?
|
| tau Proteins | 1 | 2019 | 2095 | 0.080 |
Why?
|
| Disease Models, Animal | 3 | 2012 | 18255 | 0.070 |
Why?
|
| Exercise Test | 1 | 2016 | 2127 | 0.070 |
Why?
|
| Guanfacine | 1 | 2008 | 51 | 0.070 |
Why?
|
| Feasibility Studies | 1 | 2018 | 5247 | 0.070 |
Why?
|
| Brain Concussion | 1 | 2019 | 1404 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2002 | 12794 | 0.070 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 1 | 2008 | 91 | 0.070 |
Why?
|
| Psychotherapy | 1 | 2016 | 1647 | 0.070 |
Why?
|
| Overweight | 1 | 2017 | 2417 | 0.070 |
Why?
|
| Self Report | 1 | 2018 | 3725 | 0.070 |
Why?
|
| Pituitary-Adrenal Function Tests | 2 | 2003 | 30 | 0.060 |
Why?
|
| Substance-Related Disorders | 2 | 2018 | 4420 | 0.060 |
Why?
|
| Cosyntropin | 1 | 2004 | 34 | 0.060 |
Why?
|
| Testosterone | 2 | 2017 | 2472 | 0.060 |
Why?
|
| Executive Function | 1 | 2013 | 1392 | 0.060 |
Why?
|
| Urban Population | 2 | 2003 | 2036 | 0.060 |
Why?
|
| Depressive Disorder, Major | 2 | 2018 | 4762 | 0.060 |
Why?
|
| Dietary Carbohydrates | 1 | 2009 | 891 | 0.060 |
Why?
|
| Antidepressive Agents | 1 | 2016 | 2897 | 0.060 |
Why?
|
| Nicotinic Agonists | 1 | 2006 | 265 | 0.060 |
Why?
|
| Corticotropin-Releasing Hormone | 2 | 2003 | 361 | 0.060 |
Why?
|
| Adaptation, Physiological | 1 | 2010 | 1301 | 0.060 |
Why?
|
| Adrenocorticotropic Hormone | 2 | 2003 | 618 | 0.050 |
Why?
|
| Emotions | 2 | 2012 | 2739 | 0.050 |
Why?
|
| Adolescent | 8 | 2018 | 88326 | 0.050 |
Why?
|
| Norepinephrine | 3 | 2002 | 897 | 0.050 |
Why?
|
| Catecholamines | 2 | 2001 | 386 | 0.050 |
Why?
|
| Serotonin | 3 | 1999 | 1041 | 0.050 |
Why?
|
| Analysis of Variance | 3 | 2006 | 6228 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2019 | 6484 | 0.050 |
Why?
|
| 20-alpha-Dihydroprogesterone | 1 | 2001 | 2 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2018 | 3429 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 5 | 2002 | 8181 | 0.050 |
Why?
|
| Acoustic Stimulation | 2 | 2005 | 1235 | 0.050 |
Why?
|
| Behavior | 1 | 2004 | 541 | 0.050 |
Why?
|
| Cognition Disorders | 2 | 2009 | 3980 | 0.050 |
Why?
|
| Task Performance and Analysis | 3 | 2013 | 763 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 1 | 2014 | 4415 | 0.050 |
Why?
|
| Teaching | 1 | 2009 | 1170 | 0.050 |
Why?
|
| Nicotine | 1 | 2006 | 680 | 0.050 |
Why?
|
| Avoidance Learning | 1 | 2002 | 248 | 0.050 |
Why?
|
| Child Abuse, Sexual | 1 | 2003 | 403 | 0.040 |
Why?
|
| Methoxyhydroxyphenylglycol | 1 | 2000 | 93 | 0.040 |
Why?
|
| Social Behavior Disorders | 1 | 2000 | 96 | 0.040 |
Why?
|
| Arousal | 2 | 2003 | 1166 | 0.040 |
Why?
|
| Antipsychotic Agents | 1 | 2013 | 3067 | 0.040 |
Why?
|
| Survival | 1 | 2000 | 161 | 0.040 |
Why?
|
| Dopamine | 2 | 1999 | 1607 | 0.040 |
Why?
|
| Reference Values | 1 | 2006 | 4920 | 0.040 |
Why?
|
| Afghanistan | 1 | 2019 | 78 | 0.040 |
Why?
|
| Iraq | 1 | 2019 | 92 | 0.040 |
Why?
|
| Social Isolation | 1 | 2001 | 364 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2017 | 26129 | 0.040 |
Why?
|
| Fluvoxamine | 1 | 1998 | 78 | 0.040 |
Why?
|
| Repression-Sensitization | 1 | 1997 | 1 | 0.040 |
Why?
|
| Life Change Events | 3 | 2012 | 952 | 0.040 |
Why?
|
| Estrogens | 1 | 2004 | 1522 | 0.040 |
Why?
|
| Electric Stimulation | 1 | 2002 | 1736 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2021 | 983 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2020 | 54423 | 0.030 |
Why?
|
| Mice | 4 | 2013 | 81539 | 0.030 |
Why?
|
| Rats | 5 | 2002 | 23741 | 0.030 |
Why?
|
| Biogenic Monoamines | 1 | 1996 | 50 | 0.030 |
Why?
|
| Breath Tests | 1 | 2018 | 299 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2003 | 1948 | 0.030 |
Why?
|
| Aged | 7 | 2019 | 169310 | 0.030 |
Why?
|
| Urinalysis | 1 | 2018 | 368 | 0.030 |
Why?
|
| Blast Injuries | 1 | 2019 | 322 | 0.030 |
Why?
|
| Heart Rate | 2 | 2012 | 4195 | 0.030 |
Why?
|
| Sertraline | 1 | 2016 | 209 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2014 | 12690 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2021 | 1188 | 0.030 |
Why?
|
| Telephone | 1 | 2018 | 627 | 0.030 |
Why?
|
| Models, Biological | 1 | 2010 | 9469 | 0.030 |
Why?
|
| United States | 4 | 2015 | 72340 | 0.030 |
Why?
|
| Violence | 1 | 2000 | 937 | 0.030 |
Why?
|
| Pyrrolidinones | 1 | 1994 | 116 | 0.030 |
Why?
|
| Dopamine Antagonists | 1 | 1994 | 288 | 0.030 |
Why?
|
| Neuronal Plasticity | 1 | 2002 | 1436 | 0.030 |
Why?
|
| Butyric Acid | 1 | 2013 | 51 | 0.030 |
Why?
|
| Neurologic Examination | 1 | 1997 | 916 | 0.030 |
Why?
|
| Recurrence | 1 | 2006 | 8466 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2017 | 64685 | 0.030 |
Why?
|
| Nerve Degeneration | 1 | 1997 | 748 | 0.030 |
Why?
|
| Adaptation, Psychological | 1 | 2003 | 2629 | 0.030 |
Why?
|
| Hippocampus | 2 | 2012 | 3766 | 0.030 |
Why?
|
| Anti-Anxiety Agents | 1 | 1994 | 397 | 0.020 |
Why?
|
| Circadian Rhythm | 1 | 2003 | 2576 | 0.020 |
Why?
|
| Off-Label Use | 1 | 2013 | 185 | 0.020 |
Why?
|
| Neurons | 2 | 2002 | 9463 | 0.020 |
Why?
|
| Primary Health Care | 2 | 2014 | 4687 | 0.020 |
Why?
|
| Wounds and Injuries | 1 | 2003 | 2492 | 0.020 |
Why?
|
| Desipramine | 1 | 1991 | 182 | 0.020 |
Why?
|
| Triazoles | 1 | 2016 | 903 | 0.020 |
Why?
|
| Risk Factors | 4 | 2012 | 74213 | 0.020 |
Why?
|
| Research Design | 1 | 2006 | 6180 | 0.020 |
Why?
|
| Neuropsychological Tests | 2 | 2019 | 7054 | 0.020 |
Why?
|
| Death, Sudden | 1 | 1991 | 301 | 0.020 |
Why?
|
| Amygdala | 1 | 1996 | 1354 | 0.020 |
Why?
|
| Psychometrics | 2 | 2012 | 3065 | 0.020 |
Why?
|
| Electromyography | 1 | 2012 | 1394 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2001 | 9319 | 0.020 |
Why?
|
| Psychotic Disorders | 1 | 2001 | 3223 | 0.020 |
Why?
|
| Piperazines | 1 | 2016 | 2523 | 0.020 |
Why?
|
| Aging | 1 | 2004 | 8710 | 0.020 |
Why?
|
| Time Factors | 3 | 2013 | 39969 | 0.020 |
Why?
|
| Blinking | 1 | 2005 | 133 | 0.010 |
Why?
|
| Placebo Effect | 1 | 2009 | 518 | 0.010 |
Why?
|
| Corticosterone | 2 | 1996 | 305 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2000 | 8481 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 8527 | 0.010 |
Why?
|
| Neurosecretory Systems | 1 | 2003 | 223 | 0.010 |
Why?
|
| Prevalence | 2 | 2014 | 15733 | 0.010 |
Why?
|
| Problem Solving | 1 | 2004 | 443 | 0.010 |
Why?
|
| Cerebrovascular Circulation | 1 | 1992 | 2727 | 0.010 |
Why?
|
| Boston | 1 | 2014 | 9327 | 0.010 |
Why?
|
| Anxiety Disorders | 1 | 2012 | 2720 | 0.010 |
Why?
|
| Personality Inventory | 1 | 2003 | 1019 | 0.010 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2001 | 186 | 0.010 |
Why?
|
| Connecticut | 1 | 2000 | 364 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2017 | 12953 | 0.010 |
Why?
|
| Mental Health | 1 | 2014 | 3250 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 7828 | 0.010 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 1999 | 156 | 0.010 |
Why?
|
| Placebos | 1 | 2003 | 1667 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 10212 | 0.010 |
Why?
|
| Poverty Areas | 1 | 2000 | 263 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2021 | 80647 | 0.010 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 1999 | 177 | 0.010 |
Why?
|
| Epinephrine | 1 | 2002 | 792 | 0.010 |
Why?
|
| Oxidopamine | 1 | 1999 | 172 | 0.010 |
Why?
|
| Adrenergic Agents | 1 | 1999 | 74 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 36426 | 0.010 |
Why?
|
| Child | 6 | 2005 | 80158 | 0.010 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 1999 | 432 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 1998 | 614 | 0.010 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2003 | 1988 | 0.010 |
Why?
|
| 3,4-Dihydroxyphenylacetic Acid | 1 | 1996 | 63 | 0.010 |
Why?
|
| Akathisia, Drug-Induced | 1 | 1997 | 67 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 14608 | 0.010 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 1991 | 3708 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2004 | 6345 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 15936 | 0.010 |
Why?
|
| Acute Disease | 1 | 2004 | 7237 | 0.010 |
Why?
|
| Adolescent Behavior | 1 | 2000 | 1190 | 0.010 |
Why?
|
| Nucleus Accumbens | 1 | 1994 | 366 | 0.010 |
Why?
|
| Cognition | 1 | 2009 | 6992 | 0.010 |
Why?
|
| Glycine | 1 | 1994 | 663 | 0.010 |
Why?
|
| Recovery of Function | 1 | 2001 | 2979 | 0.010 |
Why?
|
| Memory | 1 | 1999 | 2193 | 0.010 |
Why?
|
| Ventricular Fibrillation | 1 | 1991 | 537 | 0.000 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1992 | 1068 | 0.000 |
Why?
|
| Heart Arrest | 1 | 1991 | 1514 | 0.000 |
Why?
|